Timing of Cardio-Kidney Protection With SGLT2 Inhibitor varies in trials

Herat failure benefits occur early
MACE events evident early
Cardiovascular deaths & kidney outcome benefits much later

ahajournals.org/doi/10.1161/CI…

Brendon Neuen Muthu Vaduganathan et al

Download our new and improved Abridged Standards of Care (SOC), the go-to guide for primary care professionals, available for FREE. For the first time ever, we’ve condensed the SOC into easy to ready graphics. Don’t delay, download today! bit.ly/44gzZm1

Pros of inpatient SGLT2i use. AACE
endocrinepractice.org/article/S1530-…

#CGM and #GLP1 for #T2D

pubmed.ncbi.nlm.nih.gov/38666194/

If you are a clinician, you will love this guide ArodaMD ADA Professional Publications

Circulating metabolomic markers in association with overall burden of microvascular complications in type 1 diabetes Viktor Rotbain Curovic Tarunveer Singh Ahluwalia Peter Rossing Steno Diabetes Center Copenhagen

Read more here 👉 bit.ly/446Op88

(1/12) Welcome to our Tutorial on recent hot topics in #CGM use in type 2 diabetes #T2D . Follow this thread to learn more from our expert faculty, Dr. Rozalina McCoy Rozalina (Grubina) McCoy, MD MS, Associate Professor and endocrinologist specializing in #diabetes care at University of Maryland.

Circulating metabolomic markers in association with overall burden of microvascular complications in type 1 diabetes Viktor Rotbain Curovic Tarunveer Singh Ahluwalia Peter Rossing Steno Diabetes Center Copenhagen

Read more here 👉 bit.ly/446Op88

Watch as Dr. Robert Gabbay Dr. Bob gives us an overview of the 2024 Standards of Care in Diabetes- Obesity & Weight Management for the Prevention & Treatment of Type 2 Diabetes youtu.be/sBC1BXFoIOs?si…. For this and more visit: professional.diabetes.org/standards-of-c…

Honored to work with this great group of ADA staff and volunteers on this effort Nuha ElSayed, MD, MMSc george bakris Ian de Boer Dr. Bob Rozalina (Grubina) McCoy, MD MS Connie Rhee

diabetesjournals.org/clinical/artic…

How can we prioritise accelerated therapeutic implementation of the 'four pillars' of GDMT for diabetes & CKD?

-RASi
-SGLT2i
-ns-MRA
-GLP-1RA

Muthu Vaduganathan Katherine Tuttle & I outline what an 'accelerated, risk-based approach' might look like

Circulation ahajournals.org/doi/10.1161/CI…

Our new and improved Abridged Standards of Care (SOC), the go-to guide for primary care professionals, is now available for FREE!!! For the first time ever, we’ve condensed the SOC into easy to ready graphics. Don’t delay, download today! bit.ly/44gzZm1

Powerful bottom line ⁦Katherine Tuttle⁩ - people with #diabetes must urgently be treated early - prevent deaths, save kidneys, hearts, wellbeing
True expertise - telling it like it is
⁦World Kidney Day⁩ ⁦World Congress of Nephrology⁩ #isnwcn

Professor Valerie Luyckx showing a way forward. Time to do better worldwide!

So excited for this talk on diabetes and obesity agents in pregnancy! What is the optimal approach with Dr Stacey Ehrenberg! ⁦Cleveland Clinic⁩ ⁦AJMC⁩

🤔🩺 Calling all with diabetes! 🤔 Questions about diabetes-related kidney disease?
Check out ADA’s “Guidelines InSight” infographic! 💡💪 Simplifying guidelines. For more infographics, visit: lnkd.in/eHDvG228 📚🔍 Stay informed, empowered! ❤️🤍 #DiabetesAwareness …

Research| In a PCORI-funded study examining the effectiveness of #diabetes drugs in adults at moderate risk for CVD, GLP-1RA and SGLT2i reduced the risk of CV events compared to DPP-4i, while sulfonylurea increased it.
👉 rdcu.be/dDvgQ

New Review! Combination therapy for kidney disease in people with diabetes by D. van Raalte, Petter Bjornstad, M.D., D. Cherney, I. de Boer, P. Fioretto, D. Gordin, Frederik Persson, Sylvia Rosas,MD,MSCE, Peter Rossing, J. Schaub, Katherine Tuttle, Sushrut Waikar & H. Heerspink go.nature.com/4aB7lh8

GLP-1RA and SGLT2i may be the preferred glucose-lowering agents for cardiovascular risk reduction in patients at moderate baseline risk for CVD.

Joshua Neumiller Victor Montori, MD 💙 Joshua Neumiller

Transition from an eGFR-based to a risk-based approach to CKD care from KDIGO #Nephpearls

📌 Practice Point 2.2.1: A 5-year kidney failure risk of 3%–5% can be used to determine need for nephrology referral in addition to criteria based on eGFR or urine ACR, and other…

Cost-effectiveness analysis of two interventions to promote physical activity in a multiethnic population at high risk of diabetes💲 🏃 Prof Kamlesh Khunti

Learn more from this economic evaluation of the 48-month PROPELS trial
👇
bit.ly/3IVabla